Skip to main content

Table 2 Performance of the early detection model based on ctDNA methylation in the training and test sets

From: Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case–control study

Patient group Youden's index best High specificity High sensitivity
Tested Positive Positive rate (%) Tested Positive Positive rate (%) Tested Positive Positive rate (%)
Training set
Stage I 34 27 79.4% (62.1–91.2%) 34 23 67.6% (49.4–82.6%) 34 28 82.4% (65.5–93.2%)
Stage II 54 48 88.9% (77.3–95.8%) 54 46 85.2% (72.8–93.4%) 54 48 88.9% (77.4–95.8%)
Stage III 35 32 91.4% (76.9–98.2%) 35 28 80.0% (63.1–91.6%) 35 33 94.3% (80.9–99.3%)
Stage IV 26 25 96.2% (80.3–99.9%) 26 23 88.5% (69.7–97.5%) 26 25 96.2% (80.3–99.9%)
All cancer 149 132 88.6% (82.4–93.2%) 149 120 80.6% (73.2–86.6%) 149 134 89.9% (83.9–94.3%)
Healthy control 149 16 10.7% (6.3–16.9%) 149 8 5.4% (2.4–10.3%) 149 21 14.1% (9.0–20.7%)
Test set
Stage I 17 12 70.6% (43.9–89.6%) 17 11 64.7% (38.2–85.8%) 17 12 70.6% (44.0–89.7%)
Stage II 25 22 88.0% (68.6–97.4%) 25 22 88.0% (68.8–97.5%) 25 22 88.0% (68.6–97.4%)
Stage III 15 13 86.7% (59.6–98.4%) 15 12 80.0% (52.0–95.7%) 15 13 86.7% (59.6–98.4%)
Stage IV 10 9 90.0% (55.2–99.7%) 10 9 90.0% (55.4–99.7%) 10 9 90.0% (55.6–99.7%)
All cancer 67 56 83.6% (72.5–91.6%) 67 54 80.6% (69.1–89.3%) 67 56 83.6% (72.4–91.6%)
Healthy control 74 6 8.1% (3.0–16.8%) 74 3 4.1% (0.8–11.4%) 74 6 8.1% (3.0–16.9%)